HK Stock Market Move | Peg Bio-Pharmaceuticals Holding-B (02565) rose by nearly 19%. The company is deeply cultivating the chronic disease metabolism field, extending the lock-up period to demonstrate long-term confidence.

Pegbio Pharmaceuticals-B (02565) showed strong momentum today, with the highest increase during trading reaching 18.91%, closing at 29.3 Hong Kong dollars, with a trading volume of 59.6598 million Hong Kong dollars. In terms of news, Pegbio Pharmaceuticals recently announced that cornerstone investors have agreed not to reduce their holdings in any way from the voluntary lock-up expiration date (April 30) until May 20. The company believes that the extension of the lock-up period indicates that cornerstone investors have confidence in the company's future prospects based on its research and development capabilities in advancing technology and significant clinical milestones achieved. Shuiku Zhonghua pointed out earlier that the company is one of the few domestically producing pharmaceutical polyethylene glycol raw materials independently, and integrating them into the entire process of developing drugs for chronic diseases. By targeting the research and development of innovative molecular entities with "new targets, new action sites, and new mechanisms of action", it has built a diversified product pipeline with mechanism complementarity, clinical value, and benefit advantages.